Antipsychotic Combination Therapy Guidelines

Introduction to Combination Therapy

The American Academy of Child and Adolescent Psychiatry states that there is limited evidence for using two antipsychotics as an initial treatment approach or as a specific endpoint for treatment, and recommends against combining two antipsychotics from the same class without clear justification 1
The World Federation of Societies of Biological Psychiatry guidelines recommend that antipsychotic polypharmacy should only be considered in certain individual cases, such as patients with treatment-resistant schizophrenia, and that the combination of two atypical antipsychotics is not recommended as a standard treatment approach 2

The combination of aripiprazole and olanzapine offers no clear therapeutic advantage over monotherapy for most patients, while substantially increasing the risk of adverse effects, including metabolic syndrome, sedation, and extrapyramidal symptoms 2
The National Institute for Health and Care Excellence allows adding an additional antipsychotic to augment clozapine treatment if clozapine monotherapy has proven ineffective, but this is the only guideline-supported scenario for combining two antipsychotics 2

Optimize monotherapy first before considering any combination, with a systematic 6-8 week trial at adequate doses completed before concluding an agent is ineffective 1
If switching between agents, cross-titrate gradually over 1-2 weeks, rather than maintaining both long-term 2
If true treatment resistance is present, consider clozapine monotherapy rather than combining two atypical antipsychotics 2

Combining aripiprazole with olanzapine substantially increases metabolic risk, negating aripiprazole's metabolic advantages, according to the Journal of the National Comprehensive Cancer Network 3
Baseline and ongoing metabolic monitoring is required if combination is unavoidable, including BMI, waist circumference, blood pressure, fasting glucose, and lipid panel at baseline, 3 months, and annually 4

Never combine two atypical antipsychotics as a first-line approach without documented failure of adequate monotherapy trials, as recommended by the American Academy of Child and Adolescent Psychiatry and the World Federation of Societies of Biological Psychiatry 1, 2
Avoid assuming "more is better" — polypharmacy increases adverse effects without proportional efficacy gains in most cases, according to the World Federation of Societies of Biological Psychiatry 2
Do not use combination therapy to "cover neurotransmitter bases" based on theoretical mechanisms — this lacks empirical support, as stated by the American Academy of Child and Adolescent Psychiatry 1